Non-toxic goitre (ICD-10: E04), Hyperthyroidism (ICD-10: E05)
Conditions
Interventions
Group 1: Patients whose pretherapeutic dosimetry prior to radioiodine therapy was performed using the Marinelli equation.
Group 2: Patients whose pretherapeutic dosimetry prior to radioiodine therapy
Sponsors
Nuklearmedizinische Klinik, Medizinische Universität Lausitz - Carl Thiem
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Benign thyroid disease Radioiodine uptake test performed between January 1st 2022 and December 31st 2025 at the Medizinische Universität Lausitz - Carl Thiem
Exclusion criteria
Exclusion criteria: Malignant thyroid disease Additional administration of radioiodine during the same inpatient stay Radioiodine therapy not completed by December 31st 2025
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thyroid volume, blood parameters (TSH, fT3, fT4), thyroid uptake on scintigraphy, and the patient's requirement for thyroid hormone replacement therapy. Endpoints are assessed before and after radioiodine therapy and compared. All measurements are performed as part of routine guideline-based diagnostic work-up and treatment, without any additional study-related burden for the patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference between the planned and the achieved absorbed radiation dose to the thyroid. The planned absorbed dose is determined before therapy during an interdisciplinary conference involving nuclear medicine physicians and medical physics experts. The achieved absorbed dose is calculated after completion of radioiodine therapy in accordance with current clinical guidelines. | — |
Countries
Germany
Contacts
Public ContactPatrick Heilfort
Nuklearmedizinische Klinik, Medizinische Universität Lausitz - Carl Thiem
Outcome results
None listed